The brand name for insulin degludec is Tresiba [1][2]. Tresiba is an ultra-long-acting basal insulin approved for the treatment of diabetes mellitus in adults and children aged one year and older [1][3].
What is Tresiba used for?
Tresiba is indicated for the improvement of glycemic control in patients with diabetes mellitus [1]. It is a basal insulin, meaning it provides a background level of insulin throughout the day and night [4].
How does Tresiba work?
Insulin degludec, the active ingredient in Tresiba, is an analog of human insulin designed to have an ultra-long duration of action [2]. It forms multi-hexamers upon injection, which then slowly dissociate into di-hexamers and finally mono-hexamers, allowing for a sustained release of active insulin into the bloodstream over an extended period [5]. This extended duration of action can help to stabilize blood glucose levels [4].
When does Tresiba's patent expire?
Patent information for Tresiba, and its active ingredient insulin degludec, can be found on resources like DrugPatentWatch.com [6]. Patent expiry dates determine when generic versions of the drug can potentially enter the market [7].
Who makes Tresiba?
Tresiba is manufactured by Novo Nordisk [1].
How does Tresiba compare to other insulins?
Tresiba is an ultra-long-acting basal insulin. It offers a longer duration of action than other basal insulins such as insulin glargine (Lantus, Basaglar) or insulin detemir (Levemir) [4][8]. This prolonged action may offer benefits in terms of glycemic control and flexibility in dosing timing [4].
What are the side effects of Tresiba?
Common side effects associated with Tresiba include hypoglycemia (low blood sugar), injection site reactions, and allergic reactions [1]. Hypoglycemia is the most common adverse event associated with insulin therapy [3].
Can Tresiba be used by children?
Yes, Tresiba is approved for use in children aged one year and older with diabetes mellitus [1][3].
What is the dosage for Tresiba?
Dosage for Tresiba is individualized based on the patient's needs and should be determined by a healthcare professional [1].
What is the difference between Tresiba and other insulins like Levemir or Lantus?
The primary difference lies in their duration of action. Tresiba (insulin degludec) is an ultra-long-acting basal insulin, while Levemir (insulin detemir) and Lantus (insulin glargine) are considered long-acting basal insulins. Tresiba's action profile is generally longer and more predictable than that of Levemir or Lantus [4][8].
Sources:
[1] https://www.tresiba.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392263/
[3] https://www.nps.org.au/news/tresiba-insulin-degludec-is-now-listed-on-the-pbs
[4] https://diabetesjournals.org/care/article/37/12/3341/45859/Insulin-Degludec-an-Ultra-Long-Acting-Basal-Insulin
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791310/
[6] https://drugpatentwatch.com/
[7] https://www.fda.gov/drugs/patent-certification-exclusivity/patent-listing-peoples-herbal-remedies-inc-pharmaceutical-products
[8] https://www.verywellhealth.com/insulin-types-and-how-to-use-them-1087402